Your session is about to expire
← Back to Search
vixarelimab for Prurigo Nodularis
Study Summary
This trial is studying Vixarelimab to see if it is effective, safe, and tolerated in people with prurigo nodularis.
- Prurigo Nodularis
- Itchiness
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is this particular test subjects to patients who are over 30 years old?
"The age requirements to join this study are between 18 and 80 years old."
Are there any patients required for this research project?
"While this trial is not recruiting patients at the current moment, that may change in the future. According to clinicaltrials.gov, which last updated information on this study on September 26th, 2022, this research was first posted March 11st, 2019. There are other medical trials currently enrolling patients however; 39 in total."
Can you tell us about other times vixarelimab has been tested in a medical setting?
"vixarelimab was first studied at Site 1138 in 2019. Since then, there have been 18290 completed trials worldwide. Currently, 1 trial is still active and many of these studies are conducted in Fairborn, Ohio."
Might I be eligible to take part in this clinical trial?
"The itchiness of the skin is a requisite for any would-be participant and they must also fall in the age bracket of 18 to 80. Currently, this study requires 190 individuals."
Is this a novel clinical trial?
"Vixarelimab has been under investigation since 2019, when the first clinical trial was conducted by Kiniksa Pharmaceuticals. This initial study included 190 participants. Vixarelimab completed Phase 2 drug approval in 2019 and is only being studied in one active trial today, sponsored again by Kiniksa Pharmaceuticals."
In how many distinct locations is this trial being conducted?
"This study has many locations with Site 1121 in Fairborn, Site 1167 in Los Angeles, and Site 1118 in Troy being a few of the available 35 options."
Can you please give an overview of the risks associated with vixarelimab?
"While there is some data indicating that vixarelimab is safe, as this is only a Phase 2 trial, we at Power score its safety at a 2."
Share this study with friends
Copy Link
Messenger